Online citations, reference lists, and bibliographies.
← Back to Search

Albumin Nanoparticles As Nanocarriers For Drug Delivery: Focusing On Antibody And Nanobody Delivery And Albumin-based Drugs

Elmira Karami, M. Behdani, F. Kazemi-Lomedasht
Published 2020 · Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
Abstract Given that albumin has important roles in human body, it can be used in the field of medicine and disease treatment. In recent years, albumin is used as a carries in disease diagnosis and treatment. Therapeutic drugs have some disadvantages such as low solubility, shallow absorption and many side effects all of which can be overcome using nanocarriers like albumin. In this article, we reviewed different types of albumin (human, bovine, and egg) and various methods in producing and transporting albumin. We also discussed the ability of albumin as nanoparticle in reducing drug side effects and increasing their stability.
This paper references
10.1016/j.biomaterials.2013.10.001
Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles.
Raimond Heukers (2014)
10.1016/j.colsurfb.2012.04.036
Characterization and side effect analysis of a newly designed nanoemulsion targeting human serum albumin for drug delivery.
A. Divsalar (2012)
10.1021/bc800317a
Antigen delivery with poly(propylacrylic acid) conjugation enhances MHC-1 presentation and T-cell activation.
Suzanne Flanary (2009)
10.1074/jbc.M802555200
Pseudo-esterase Activity of Human Albumin
O. Lockridge (2008)
10.1080/15569543.2016.1244552
Development of a recombinant camelid specific diabody against the heminecrolysin fraction of Hemiscorpius lepturus scorpion
Maryam Bagheri (2017)
10.1016/j.msec.2016.12.108
Prodrug encapsulated albumin nanoparticles as an alternative approach to manifest anti-proliferative effects of suicide gene therapy.
Bulbul Tirkey (2017)
10.1016/j.jconrel.2011.09.069
Impact of albumin on drug delivery--new applications on the horizon.
B. Elsadek (2012)
10.1016/j.jconrel.2012.11.007
Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells.
I. Altintaş (2013)
10.1080/17425247.2016.1193149
Albumin nanostructures as advanced drug delivery systems
Mahdi Karimi (2016)
10.1002/anie.201300958
Glucose- and pH-responsive controlled release of cargo from protein-gated carbohydrate-functionalized mesoporous silica nanocontainers.
Shanshan Wu (2013)
10.1007/s00262-006-0180-4
Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies
R. Roovers (2006)
10.3390/ANTIB4030141
Pre-Clinical Intravenous Serum Pharmacokinetics of Albumin Binding and Non-Half-Life Extended Nanobodies®
Sven Hoefman (2015)
10.1016/j.ejps.2011.10.015
Targeting epidermal growth factor receptor in tumors: from conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies.
I. Altintaş (2012)
10.1016/J.MOLIMM.2006.08.007
Generation of llama single-domain antibodies against methotrexate, a prototypical hapten.
Nidia Alvarez-Rueda (2007)
10.1016/S0168-3659(01)00420-5
Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics.
F. Dosio (2001)
10.1126/SCIENCE.2727704
Three-dimensional structure of human serum albumin.
D. Carter (1989)
10.22038/ijbms.2018.24898.6183
Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function
F. Kazemi-Lomedasht (2018)
10.2174/1389557053175335
Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs.
J. M. Irache (2005)
10.1016/S1359-6349(10)70002-1
Nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer
J. Cortés (2010)
10.4172/2157-7439.1000176
Albumin as a Delivery Carrier for Rheumatoid Arthritis
K. Ren (2013)
10.1002/jps.23455
A novel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicity.
A. Yuan (2013)
10.1016/j.biomaterials.2013.11.001
Enzyme delivery using the 30Kc19 protein and human serum albumin nanoparticles.
Hong Jai Lee (2014)
10.1093/protein/gzx022
Half-life extension using serum albumin-binding DARPin® domains
Daniel Steiner (2017)
10.2147/IJN.S8501
Optimization of the preparation process of vinblastine sulfate (VBLS)-loaded folateconjugated bovine serum albumin (BSA) nanoparticles for tumor-targeted drug delivery using response surface methodology (RSM)
Y. Zu (2009)
10.2147/IJN.S12918
Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles
D. Zhao (2010)
10.2174/0929867326666190320105316
Structural basis of drug recognition by human serum albumin.
Loris Leboffe (2019)
10.1002/mabi.201500006
An Oligonucleotide Transfection Vector Based on HSA and PDMAEMA Conjugation: Effect of Polymer Molecular Weight on Cell Proliferation and on Multicellular Tumor Spheroids.
Yanyan Jiang (2015)
10.1002/BIP.20539
Nanogels prepared by self-assembly of oppositely charged globular proteins.
S. Yu (2006)
10.1007/s10853-019-03486-9
Biotin-modified bovine serum albumin nanoparticles as a potential drug delivery system for paclitaxel
Danfeng Wang (2019)
10.1016/S0168-3659(97)00252-6
DNA-polycation nanospheres as non-viral gene delivery vehicles.
K. Leong (1998)
The role of serum proteins in acid-base equilibria.
J. Figge (1991)
10.1016/S0167-4838(96)00221-X
Probing the cysteine 34 residue in human serum albumin using fluorescence techniques.
R. Narazaki (1997)
10.1016/j.colsurfb.2018.03.046
Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers.
Kaustubh A Gawde (2018)
10.1016/j.jconrel.2010.05.022
A novel lipoprotein-mimic nanocarrier composed of the modified protein and lipid for tumor cell targeting delivery.
Y. Xu (2010)
10.1016/S0378-5173(99)00370-1
Desolvation process and surface characterisation of protein nanoparticles.
C. Weber (2000)
10.1016/S0378-4347(01)00108-6
Structure and properties of ovalbumin.
J. Huntington (2001)
10.22038/IJBMS.2016.7820
Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3)
V. Homayouni (2016)
10.1016/j.ijpharm.2014.05.056
Albumin nanoparticles for the delivery of gabapentin: preparation, characterization and pharmacodynamic studies.
B. Wilson (2014)
10.1089/MAB.2016.0001
Production and Characterization of Novel Camel Single Domain Antibody Targeting Mouse Vascular Endothelial Growth Factor.
Kazemi-LomedashtFatemeh (2016)
10.1007/s00280-019-03832-3
Investigation of anti-tumor effect of doxorubicin-loaded human serum albumin nanoparticles prepared by a desolvation technique
Kotaro Kimura (2019)
10.1039/C8TB01613E
Safety of nanoparticles based on albumin-polymer conjugates as a carrier of nucleotides for pancreatic cancer therapy.
K. Taguchi (2018)
10.1021/bc700319r
Modulation of antibody pharmacokinetics by chemical polysialylation.
A. Constantinou (2008)
10.1038/cgt.2016.76
Intrabody targeting vascular endothelial growth factor receptor-2 mediates downregulation of surface localization
E. Alirahimi (2017)
10.1016/j.foodchem.2015.06.109
Affinity of rosmarinic acid to human serum albumin and its effect on protein conformation stability.
Xin Peng (2016)
10.1080/07391102.2019.1638303
Interaction, cytotoxicity and sustained release assessment of a novel anti-tumor agent using bovine serum albumin nanocarrier
Nassim Fattahian Kalhor (2019)
10.1177/1078155208098584
Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer
G. Dranitsaris (2009)
10.1016/J.NANO.2007.10.021
Nanoparticle albumin bound (nab) technology: targeting tumors through the endothelial gp60 receptor and SPARC
N. Desai (2007)
10.1007/s11051-013-1651-0
The novel albumin–chitosan core–shell nanoparticles for gene delivery: preparation, optimization and cell uptake investigation
Mahdi Karimi (2013)
10.1016/J.COSSMS.2004.01.010
Engineered and designed peptide-based fibrous biomaterials
C. MacPhee (2004)
10.1007/978-981-10-2116-9_6
Nanoparticle Albumin-Bound Paclitaxel (Abraxane®)
N. Desai (2016)
10.1016/J.FOODHYD.2014.09.021
Structural properties of condensed ovalbumin systems following application of high pressure
Sobhan Savadkoohi (2016)
10.1016/j.jconrel.2011.07.031
Albumin-based nanoparticles as potential controlled release drug delivery systems.
Ahmed O Elzoghby (2012)
10.1016/J.FOODHYD.2014.02.009
Phase separation behavior and structural analysis of ovalbumin–gum arabic complex coacervation
Fuge Niu (2015)
10.1177/0148607191015004476
Reviews: The Role of Albumin in Human Physiology and Pathophysiology, Part III: Albumin and Disease States
J. Doweiko (1991)
10.1016/J.APJTB.2017.06.001
An overview on application of phage display technique in immunological studies
A. Rami (2017)
10.1080/08830185.2018.1526932
Single-Domain Antibodies or Nanobodies: A Class of Next-Generation Antibodies
Farnaz Khodabakhsh (2018)
10.1016/j.ejpb.2015.07.013
Long-circulating self-assembled cholesteryl albumin nanoparticles enhance tumor accumulation of hydrophobic anticancer drug.
G. Battogtokh (2015)
10.1021/BI00406A016
Role of fructose in glycation and cross-linking of proteins.
J. McPherson (1988)
10.1016/j.addr.2007.08.044
Protein nanoparticles as drug carriers in clinical medicine.
M. Hawkins (2008)
10.1073/PNAS.91.25.12243
Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.
A. Lorenzo (1994)
10.1021/JA030104K
Protein-conjugated nanoparticles from rapid expansion of supercritical fluid solution into aqueous solution.
M. J. Meziani (2003)
10.1002/smll.200901689
Bovine serum albumin-based magnetic nanocarrier for MRI diagnosis and hyperthermic therapy: a potential theranostic approach against cancer.
M. Comes Franchini (2010)
10.1016/j.heliyon.2019.e01858
In vivo and in vitro biocompatibility study of novel microemulsion hybridized with bovine serum albumin as nanocarrier for drug delivery
Mahmoud Gharbavi (2019)
All About Albumin: Biochemistry, Genetics, and Medical Applications
T. Peters (1995)
10.1016/S0014-5793(98)01346-5
Albumin's role in steroid hormone action and the origins of vertebrates: is albumin an essential protein?
M. Baker (1998)
10.2217/nnm.14.178
Nanobody-based cancer therapy of solid tumors.
M. Kijanka (2015)
Albumin as a drug delivery and diagnostic tool and its market approved products.
Ayesha Sethi (2013)
10.5897/AJB2006.000-5072
Production of biological nanoparticles from bovine serum albumin for drug delivery
M. Rahimnejad (2006)
10.1007/s10989-019-09870-y
Functional Study of a Camelid Single Domain Anti-CD22 Antibody
F. Faraji (2019)
10.1021/bc1002295
Targeted albumin-based nanoparticles for delivery of amphipathic drugs.
Rongzuo Xu (2011)
10.1016/j.bbagen.2018.08.019
Nanobodies as novel therapeutic agents in envenomation.
E. Alirahimi (2018)
10.1021/am404734c
Self-assembled biodegradable protein-polymer vesicle as a tumor-targeted nanocarrier.
Z. Liu (2014)
10.1021/ja5038269
Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery
Yao-Rong Zheng (2014)
10.1046/J.1432-1327.2001.02107.X
High affinity binding of paclitaxel to human serum albumin.
K. Paál (2001)
10.4314/AJB.V7I25.59701
Protein nanoparticle: A unique system as drug delivery vehicles
M. Jahanshahi (2008)
10.1016/j.biomaterials.2013.08.085
Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors.
Sohee Son (2013)
10.1042/BJ20050721
The in situ observation of the temperature and pressure stability of recombinant Aspergillus aculeatus pectin methylesterase with Fourier transform IR spectroscopy reveals an unusual pressure stability of beta-helices.
Carolien Dirix (2005)
10.1002/ijc.26145
A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growth
R. Roovers (2011)
10.1093/protein/gzp091
Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon.
A. Walker (2010)
10.1016/S0168-3659(03)00014-2
Nanotechnological approaches for the delivery of macromolecules.
D. J. Crommelin (2003)
10.1016/j.ijbiomac.2018.12.143
Preparation of a highly stable drug carrier by efficient immobilization of human serum albumin (HSA) on drug-loaded magnetic iron oxide nanoparticles.
Neda Hosseinpour Moghadam (2019)
10.1016/J.COLSURFA.2018.10.080
Characterization of G4 PAMAM dendrimer complexes with 5-fluorouracil and their interactions with bovine serum albumin
Karolina Tokarczyk (2019)
10.1038/s41598-018-31933-1
Naphthol Blue Black and 99mTc-Labeled Mannosylated Human Serum Albumin (99mTc-MSA) Conjugate as a Multimodal Lymph Node Mapping Nanocarrier
J. Y. Lee (2018)
10.1016/j.ijpharm.2010.10.012
Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy.
Sie Huey Lee (2011)
10.1016/S0169-409X(02)00044-3
Nanoparticles in cancer therapy and diagnosis.
I. Brigger (2002)
10.1016/j.copbio.2011.06.012
Strategies for extended serum half-life of protein therapeutics.
R. Kontermann (2011)
10.1021/JA0343095
Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy.
I. Roy (2003)
10.1002/ART.21827
Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis.
K. Coppieters (2006)
10.1016/J.MOLLIQ.2018.06.066
Bovine serum albumin: An efficient biomacromolecule nanocarrier for improving the therapeutic efficacy of chrysin
H. Nosrati (2018)
10.1021/ACSBIOMATERIALS.9B00312
Antitumor Effect and Toxicity of an Albumin-Paclitaxel Nanocarrier System Constructed via Controllable Alkali-Induced Conformational Changes
Guangming Gong (2019)
10.1002/DDR.10157
Biopolymer albumin for diagnosis and in drug delivery
G. V. Patil (2003)
10.1038/358209A0
Atomic structure and chemistry of human serum albumin
X. M. He (1992)
10.1080/1547691X.2018.1526234
Oligoclonal selection of nanobodies targeting vascular endothelial growth factor
M. Ahadi (2018)
10.1016/S0378-5173(03)00134-0
Optimization of the preparation process for human serum albumin (HSA) nanoparticles.
K. Langer (2003)
10.1016/j.molimm.2015.01.010
Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody.
F. Kazemi-Lomedasht (2015)
10.1111/j.1423-0410.2002.tb05326.x
Beyond Expansion: Structural Studies on the Transport Roles of Human Serum Albumin
S. Curry (2002)
10.1089/MAB.2014.0086
Selection and Characterization of Specific Nanobody Against Human Immunoglobulin G.
Kazemi-LomedashtFatemeh (2015)
10.22038/IJBMS.2017.8672
In vivo immunotherapy of lung cancer using cross-species reactive vascular endothelial growth factor nanobodies
F. Kazemi-Lomedasht (2017)
10.1016/S0928-0987(00)00169-X
Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release properties.
M. Merodio (2001)
10.1529/BIOPHYSJ.104.051516
Unfolding and refolding of bovine serum albumin induced by cetylpyridinium bromide.
C. Sun (2005)
10.2147/IJN.S3061
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
E. Miele (2009)
10.1016/j.saa.2017.05.023
Alteration of human serum albumin binding properties induced by modifications: A review.
M. Maciążek-Jurczyk (2018)
10.1007/s40259-019-00392-z
The Therapeutic Potential of Nanobodies
Ivana Jovčevska (2019)
10.1021/bm501205x
Polyion complex micelle based on albumin-polymer conjugates: multifunctional oligonucleotide transfection vectors for anticancer chemotherapeutics.
Yanyan Jiang (2014)
10.1016/bs.apcsb.2014.11.002
Efficient delivery of therapeutic agents by using targeted albumin nanoparticles.
Hasan Kouchakzadeh (2015)
10.1016/j.toxlet.2011.06.027
HI 6 human serum albumin nanoparticles--development and transport over an in vitro blood-brain barrier model.
M. Dadparvar (2011)
10.1002/dta.2693
Development of a mono-specific anti-VEGF bivalent nanobody with extended plasma half-life for treatment of pathologic neovascularization.
A. Sadeghi (2019)
10.1016/j.jconrel.2018.11.017
Stimulating brain recovery after stroke using theranostic albumin nanocarriers loaded with nerve growth factor in combination therapy
T. Feczkó (2019)
10.1021/bc9002772
New strategy for the extension of the serum half-life of antibody fragments.
Sabrina Trüssel (2009)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar